Products You May Like
NEWTOWN, Pa., July 07, 2021 (GLOBE NEWSWIRE) — Helius Medical Applied sciences, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Firm”), a neurotech firm targeted on neurological wellness, at the moment introduced it is going to take part within the Annual World Congress of the Society for Mind Mapping and Therapeutics, which will probably be held from July 8-11th in Los Angeles, California.
The Firm has been chosen to obtain the Pioneer in Expertise Award through the occasion, an award introduced by the Society to path blazing firms who’ve facilitated the event of pioneering applied sciences by interdisciplinary approaches which have impacted diagnostics, therapy and healthcare supply in unprecedented methods.
Dr. Jonathan Sackier, Helius’ Co-Founder and Medical Advisor, will host a presentation through the occasion titled: From porpoise to PoNS™: the bridge of Varolio and translingual neuromodulation to handle steadiness and gait signs. The presentation will embody a dialogue of the historical past of neuromodulation, the science behind Helius’ PoNS know-how, information from trials in experimental and medical settings – together with trials targeted on a number of sclerosis, traumatic mind harm, stroke and cerebral palsy – and the PoNS gadget’s latest regulatory clearances. The presentation will probably be held on July 11th at 10 a.m. Pacific Time.
About Helius Medical Applied sciences, Inc.
Helius Medical Applied sciences is a neurotech firm targeted on neurological wellness. The Firm’s goal is to develop, license and purchase distinctive and non-invasive platform applied sciences that amplify the mind’s potential to heal itself. The Firm’s first industrial product is the Moveable Neuromodulation Stimulator (PoNSTM). For extra data, go to www.heliusmedical.com.
In regards to the PoNS™ Gadget and PoNS Therapy™
The Moveable Neuromodulation Stimulator (PoNSTM) is an progressive non-surgical gadget, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the floor of the tongue to offer therapy of gait deficit. The PoNS gadget is indicated to be used in america as a brief time period therapy of gait deficit as a result of mild-to-moderate signs from a number of sclerosis (“MS”) and is for use as an adjunct to a supervised therapeutic train program in sufferers 22 years of age and over by prescription solely. It’s licensed on the market in Canada as a category II, non-implantable, medical gadget meant as a brief time period therapy (14 weeks) of gait deficit as a result of gentle and reasonable signs from MS, and persistent steadiness deficit as a result of mild-to-moderate traumatic mind harm (“mmTBI”) and is for use along side bodily remedy. PoNS is an investigational medical gadget within the European Union (“EU”) and Australia (“AUS”). It’s presently below premarket evaluation by the AUS Therapeutic Items Administration.
Cautionary Disclaimer Assertion:
Sure statements on this information launch usually are not primarily based on historic details and represent forward-looking statements or forward-looking data inside the that means of the U.S. Non-public Securities Litigation Reform Act of 1995 and Canadian securities legal guidelines. All statements aside from statements of historic reality included on this information launch are forward-looking statements that contain dangers and uncertainties. Ahead-looking statements are sometimes recognized by phrases akin to “consider,” “proceed,” “trying forward,” “will,” “dedicated to,” “aim,” “count on,” “stay,” “hope” and comparable expressions. Such forward-looking statements embody, amongst others, statements concerning the Firm’s future strategic and operational execution, the subsequent section of the Firm’s market growth actions, medical and regulatory growth plans for the PoNS gadget, and the timing and success of the Firm’s commercialization efforts in america.
These statements contain substantial recognized and unknown dangers and uncertainties. There will be no assurance that such statements will show to be correct and precise outcomes and future occasions might differ materially from these expressed or implied by such statements. Vital components that would trigger precise outcomes to vary materially from the Firm’s expectations embody uncertainties concerning the Firm’s capital necessities to attain its enterprise targets, the affect of the COVID-19 pandemic, the Firm’s potential to coach bodily therapists within the supervision of using the PoNS Therapy, the Firm’s potential to safe contracts with rehabilitation clinics, the Firm’s potential to acquire nationwide Medicare protection and to acquire a reimbursement code in order that the PoNS gadget is roofed by Medicare and Medicaid, the Firm’s potential to construct inner industrial infrastructure, market consciousness of the PoNS gadget, future medical trials and the medical growth course of, manufacturing and provide chain dangers, potential modifications to the MCIT program, the product growth course of and FDA regulatory submission evaluation and approval course of, different growth actions, ongoing authorities regulation, and different dangers detailed once in a while within the “Threat Components” sections of the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2020, its Quarterly Report on Type 10-Q for the quarter ended March 31, 2021 and its different filings with america Securities and Alternate Fee and the Canadian securities regulators, which will be obtained from both at www.sec.gov or www.sedar.com.The reader is cautioned to not place undue reliance on any forward-looking assertion. The forward-looking statements contained on this information launch are made as of the date of this information launch and the Firm assumes no obligation to replace any forward-looking assertion or to replace the explanation why precise outcomes might differ from such statements besides to the extent required by regulation.
The Toronto Inventory Alternate has not reviewed and doesn’t settle for accountability for the adequacy or accuracy of the content material of this information launch.
Investor Relations Contact: Westwicke on behalf of Helius Medical Applied sciences, Inc. Jack Powell, Vice President investorrelations@heliusmedical.com
